An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Nkarta to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Nkarta, Inc. (NKTX) will be participating in two investor conferences to discuss its engineered natural killer cell therapies. The events include the Needham Virtual Healthcare Conference on April 9 and the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:
Needham Virtual Healthcare Conference April 9, 2024 1:30 p.m. ET – fireside chat
Canaccord Genuity Horizons in Oncology Virtual Conference April 15, 2024 1:00 p.m. ET – panel discussion
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact: Greg Mann Nkarta, Inc. gmann@nkartatx.com
FAQ
When is Nkarta, Inc. (NKTX) participating in the Needham Virtual Healthcare Conference?
Nkarta, Inc. (NKTX) will be participating in the Needham Virtual Healthcare Conference on April 9, 2024 at 1:30 p.m. ET for a fireside chat.
What is the Canaccord Genuity Horizons in Oncology Virtual Conference and when is Nkarta, Inc. (NKTX) participating?
The Canaccord Genuity Horizons in Oncology Virtual Conference is an event where Nkarta, Inc. (NKTX) will participate in a panel discussion on April 15, 2024 at 1:00 p.m. ET.
Where can investors watch the webcast of the investor conferences involving Nkarta, Inc. (NKTX)?
Investors can watch the simultaneous webcast of each event on the Investors section of Nkarta's website, www.nkartatx.com. A replay will be archived on the website for approximately 90 days.
nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.
